Compare Kraft Heinz Co (KHC) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kraft Heinz Co vs State Street SPDR S&P Biotech ETF — how do they compare? Kraft Heinz Co trades at $22.27 (market cap $26.66B), while State Street SPDR S&P Biotech ETF trades at $153.75 (market cap $10.11B). The key difference: Kraft Heinz Co is far larger — about 2.6× State Street SPDR S&P Biotech ETF's market cap, and Kraft Heinz Co pays a 7.12% dividend while State Street SPDR S&P Biotech ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Kraft Heinz Co for 129 Days and State Street SPDR S&P Biotech ETF for 38 Days on average.
| KHC | XBI | |
|---|---|---|
Market Cap | $26.66B | $10.11B |
Volume | 31,300,109 | 12,903,266 |
Sector | Consumer Staples | Broad Market / Factor |
52-Week High | $27.62 | $169.55 |
52-Week Low | $21.21 | $104.99 |
Typical Hold Time | 129 Days | 38 Days |
Enterprise Value | $42.98B | — |
Dividend Yield | 7.12% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Kraft Heinz (KHC) trades at $22.27, up 1.32% today, with a bearish technical signal but positive earnings beats in recent quarters. The company faces fundamental headwinds, including a net loss of $5.85 billion in 2025 and a negative net income margin of -13.64%, though operating cash flow remains strong at $4.46 billion. Recent news highlights turnaround efforts, such as new product launches and a $700 million reinvestment plan, amid a high dividend yield and mixed analyst sentiment.
The outlook is cautious due to profitability challenges and high debt, but the stock's low valuation (P/E of 13.04, P/B of 0.74) and consistent cash flow offer potential for value investors. Risks include sustained volume declines and competitive pressures, while the consensus price target of $24.50 suggests modest upside if turnaround initiatives gain traction.
XBI trades at $153.75, up 2.34% today, but technical indicators signal a bearish trend with resistance at $154. The ETF's modified equal-weight structure provides exposure to over 150 biotech companies, benefiting from M&A activity and positive clinical catalysts like the Merck-Moderna cancer vaccine breakthrough.
Outlook remains mixed with 100% analyst hold rating contrasting with bullish news catalysts. Key risks include high volatility, sector-specific regulatory pressures, and expense ratios higher than broader healthcare ETFs. The current technical setup near resistance requires monitoring for breakout confirmation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Kraft Heinz Co
In July 2015, Kraft merged with Heinz to create the third-largest food and beverage manufacturer in North America behind PepsiCo and Nestle and the fifth-largest player in the world. Beyond its namesake brands, the combined firm's portfolio includes Oscar Mayer, Velveeta, and Philadelphia. Outside North America, the firm's global reach includes a distribution network in Europe and emerging markets that drive around one fifth of its consolidated sales base, as its products are sold in more than 190 countries and territories.
Read more on KHC →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
